Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies
Cell host & microbe
17D; South America; antibody response; emerging virus; flavivirus; glycoprotein; immunological response; neutralizing antibodies; vaccine; yellow fever virus
The resurgence of yellow fever in South America has prompted vaccination against the etiologic agent, yellow fever virus (YFV). Current vaccines are based on a live-attenuated YF-17D virus derived from a virulent African isolate. The capacity of these vaccines to induce neutralizing antibodies against the vaccine strain is used as a surrogate for protection. However, the sensitivity of genetically distinct South American strains to vaccine-induced antibodies is unknown. We show that antiviral potency of the polyclonal antibody response in vaccinees is attenuated against an emergent Brazilian strain. This reduction was attributable to amino acid changes at two sites in central domain II of the glycoprotein E, including multiple changes at the domain I-domain II hinge, which are unique to and shared among most South American YFV strains. Our findings call for a reevaluation of current approaches to YFV immunological surveillance in South America and suggest approaches for updating vaccines.
Haslwanter, Denise; Lasso, Gorka; Wec, Anna Z.; Furtado, Nathália Dias; Raphael, Lidiane Menezes; Tse, Alexandra L.; Sun, Yan; Stransky, Stephanie; Pedreño-Lopez, Núria; Correia, Carolina Argondizo; Bornholdt, Zachary A.; Sakharkar, Mrunal; Avelino-Silva, Vivian I.; Moyer, Crystal L.; Watkins, David I.; Kallas, Esper G.; Sidoli, Simone; Walker, Laura M.; Bonaldo, Myrna C.; and Chandran, Kartik, "Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies" (2022). GW Authored Works. Paper 309.